Given the role of CSCs in therapy resistance and recurrence [227,228], targeting the EHMT1–C/EBPβ–ALDH1A1 pathway may offer a promising therapeutic strategy in ARMS [226,229]. The gene discussed is EHMT1; the disease is alveolar rhabdomyosarcoma.